X0508 4 2024-09-16 0001832168 Longboard Pharmaceuticals, Inc. LBPH 0001350416 Kaye Randall 4275 EXECUTIVE SQUARE SUITE 950 LA JOLLA CA 92037 false true false false CMO true Common Stock 2024-09-16 4 M false 16666 4.35 A 34586 D Common Stock 2024-09-16 4 S false 9366 30.886 D 25220 D Common Stock 2024-09-16 4 S false 4200 31.8148 D 21020 D Common Stock 2024-09-16 4 S false 1200 33.1246 D 19820 D Common Stock 2024-09-16 4 S false 1900 34.0359 D 17920 D Stock Option (Right to Buy) 4.35 2024-09-16 4 M false 16666 0.00 D 2033-02-08 Common Stock 16666 112967 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. The amount reported includes the 17,920 restricted stock units (RSUs) that were granted on February 8, 2024, and reported in a Form 4 filed on February 9, 2024. The RSUs will vest in four equal annual installments commencing on February 8, 2025, and the shares underlying the RSUs will be issued upon vesting and release of the RSUs. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.54 to $31.52, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.56 to $32.40, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.80 to $33.68, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.86 to $34.33, inclusive. The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023. /s/ Andrew J. Cronauer, Attorney-In-Fact 2024-09-16